Latest news

Adalvo is proud to announce the launch of our Q3 2023 Product Dossier. Offering an exclusive glimpse into the advancing strides we have made over the last quarter, reflecting Adalvo's unwavering dedication...

Adalvo is excited to announce the launch of Pomalidomide Hard Capsules 1/2/3/4mg in Canada. Our product is based on the reference brand, Pomalyst, and is indicated in the treatment of adult patients with...

Adalvo is thrilled to announce the expansion of its partnership with Teva, signing a licensing deal for a blockbuster small molecule in the oncology segment aimed at addressing rare diseases...

We are pleased to announce oursuccessful DCP submission for Pomalidomide Hard Capsules 1/2/3/4mg, upon expiry of the orphan market exclusivity. Our product is based on the reference brand, Imnovid, and is indicated...

Adalvo is proud to share a significant achievement in our pursuit to making a difference for patients around the world. Last week, the company successfully filed three distinct INN DCP applications for Azelastine+Fluticasone...

We are pleased to announce our successful DCP submission for Dapagliflozin 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners. Our product has been...

Adalvo is pleased to announce oursuccessful DCP submission for Adapalene + Benzoyl Peroxide Gel. This product has been developed in collaboration with one of our strategic partners, based on the reference...

Adalvo are pleased to announce our successful DCP submission for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray. The product has been developed...

Adalvo is thrilled to have successfully executed Dimethyl Fumarate 120/240mg Capsules in Mexico, with our esteemed partners, Corne. This successful execution marks a significant milestone in Adalvo's commitment to delivering competitive pharmaceutical solutions around...

Adalvo is delighted to highlight the expansion of its portfolio with the well-established Dimetindene Gel 0.1% (1mg/g). This product has been developed based on the reference brand Fenistil Gel, and is intended...

Adalvo is pleased to announce that the successful Pivotal BE Study for Brivaracetam Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for January 2024. Brivaracetam Film Coated...

We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets. This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients. Our Desogestrel+Ethinylestradiol...

Adalvo is pleased to announce that the successful Pivotal BE Study for Afatinib Film-Coated Tablets has been completed and we are now preparing our dossier submission which is scheduled for November 2023. Our...

We are pleased to announce our successful DCP submission for Mirabegron prolonged release tablets.  This product has been developed in collaboration with one of our strategic partners, based on the reference brand, Betmiga prolonged release...

Adalvo is pleased to announce a new collaboration with Stendhal, a Mexican pharmaceutical company that provides innovative therapies to improve the quality of life of patients, with presence in Mexico...

In our pursuit of being at the forefront of innovation, we are delighted to share the news of our second successful DCP closure for Desmopressin. While the demand has been...

Adalvo and SteinCares are pleased to announce the extension of their long-term strategic collaboration in Latin America. The companies have recently signed a basket deal for five products to be...

Adalvo is delighted to announce the successful DCP submission of our Dydrogesterone 10mg tablets. Adalvo takes great pride in being amongst the first wave of filers in the EU, with...

We are pleased to announce the successfulDCP approval for Eribulin solution for injection, 0.44mg/ml. As of today, there are no generic MA’s granted for this product. We will now progress with...

Adalvo is excited to announce that we have successfully completed our Pivotal BE program for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray.

Adalvo and EQL Pharma have established a formidable partnership, entering into a strategic licensing agreement for Mellozzan® (with active ingredient melatonin). This collaboration grants Adalvo exclusive rights to register, commercialize,...